Tag: PRRT

Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting

Josh Mailman, President of the NorCal CarciNET Community  and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…

10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

Worldwide NET Cancer Awareness Day, November 10, 2013

Name Your NET Hero, a global webinar, a bridge striped in alternating patterns of purple and white lights, walks, conferences, and more are some of the many ways people around the globe are participating in the 4th annual Worldwide NET Cancer Awareness…

New Jersey Carcinoid Cancer NETwork Conference in November, Registration through October 16

Three of the country’s leading carcinoid and neuroendocrine cancer specialists will be featured speakers for the New Jersey Carcinoid Cancer NETwork Conference. to be held on Saturday, November 2, 2013 at the Crowne Plaza in Edison, New Jersey.  Carcinoid/NETs: …

Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging Patient Program

Josh Mailman, President of the NorCal CarciNET support group and Chair of the Patient Advocate Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day …

Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients

For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in  the United States, Excel Diagnostics and Nuclear Oncology Center  in Houston, Texas, in collaboration with…

2nd World Congress on Ga-68, Molecular Imaging & Targeted Radionuclide Therapy

Chandigarh, India will be the site of the 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry:  On the Way to Personalized Medicine from February 28 through…

FDA Approves Amendment for PRRT Clinical Trial in Texas

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)     The FDA approved the first…

Pancreatic Neuroendocrine Tumors: A Rare Cancer

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…